MyFinsight
Home
Blog
About
Contact
Proceeds from the
issuance of debt, net of...
$93,886K
Proceeds from exercise of
stock options
$2,025K
Proceeds from issuances
of stock under espp
$1,510K
Maturities of marketable
securities
$181,293K
Net cash provided by
(used in) financing...
$96,608K
Net cash provided by
(used in) investing...
$25,269K
Canceled cashflow
$813K
Canceled cashflow
$156,024K
Net change in cash,
cash equivalents and...
-$6,636K
Canceled cashflow
$121,877K
Stock-based compensation
expense
$19,044K
Depreciation and
amortization
$5,605K
Change in operating
lease right-of-use...
$2,532K
Accounts payable
$2,216K
Other long-term
liabilities
$134K
Amortization of debt discount
$35K
Payments of debt issuance
costs
$813K
Purchases of marketable
securities
$153,792K
Purchases of property and
equipment
$2,232K
Net cash provided by
(used in) operating...
-$128,513K
Canceled cashflow
$29,566K
License and
collaboration revenue
$31,738K
Interest and other income
$9,867K
Net loss
-$94,318K
Prepaid expenses and
other current assets
$31,861K
Accrued expenses and
other liabilities
-$16,258K
Canceled cashflow
$41,605K
Deferred revenue
-$6,355K
Operating lease
liabilities
-$3,494K
Amortization of investment
discount (premiums)
$2,763K
Change in fair value of
derivative liabilities
$2,500K
Change in fair value of
contingent consideration...
-$514K
Change in fair value of
non-controlling equity...
$16K
Research and development
expenses-Employee Related...
$32,867K
Research and development
expenses-External Research And...
$30,077K
Stock-based compensation
$19,044K
Facility and information
technology related...
$14,438K
General and
administrative...
$13,366K
General and
administrative...
$11,951K
Other segment items
$8,575K
Depreciation and
amortization
$5,605K
Back
Back
Cash Flow
Beam Therapeutics Inc. (BEAM)
Beam Therapeutics Inc. (BEAM)
source: myfinsight.com